 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
PK/PD data, Journal: Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus. (Pubmed Central) - Jan 6, 2025
Daily administration of noiiglutide using a titration method was well tolerated by Chinese obese participants without DM and showed potential therapeutic effect for weight loss.
- HR17031 / Jiangsu Hengrui Pharma, long acting basal insulin (INS068) / Jiangsu Hengrui Pharma, noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Benefits of HR17031, a Fixed-Ratio Combination of INS068 and SHR20004, vs. Its Components Alone in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Oral Antidiabetic Drug(s) (OADs) (Poster Hall (West A4-B2); 751) - May 20, 2024 - Abstract #ADA2024ADA_3262;
This trial assessed efficacy and safety of HR17031 vs INS068 and SHR20004 in pts with T2D. In this randomized phase 2 trial, 455 Chinese adults with T2D (HbA1c 7.5%-11.0%; previous metformin
- || noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Enrollment closed: Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - Feb 20, 2024
P1, N=28, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
In this randomized phase 2 trial, 455 Chinese adults with T2D (HbA1c 7.5%-11.0%; previous metformin Recruiting --> Active, not recruiting
- || noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Enrollment open: Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - Jan 4, 2024
P1, N=28, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Clinical, P2 data, Journal: Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. (Pubmed Central) - Dec 18, 2023
Not yet recruiting --> Recruiting In obese Chinese adults without diabetes, once-daily subcutaneous noiiglutide significantly reduced body week at week 24 compared with placebo, and had a manageable safety profile, primarily involving gastrointestinal disorders.
- || noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P1 trial: Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - Nov 19, 2023
P1, N=28, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| HR17031 / Jiangsu Hengrui Pharma, long acting basal insulin (INS068) / Jiangsu Hengrui Pharma
Enrollment closed: A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - Apr 25, 2023
P2, N=455, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
In obese Chinese adults without diabetes, once-daily subcutaneous noiiglutide significantly reduced body week at week 24 compared with placebo, and had a manageable safety profile, primarily involving gastrointestinal disorders. Recruiting --> Active, not recruiting
- ||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Trial completion: A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects. (clinicaltrials.gov) - Nov 7, 2022
P2, N=128, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Unknown status --> Completed
- || HR17031 / Jiangsu Hengrui Pharma
Trial completion: Pharmacokinetics of HR17031 Injection in Healthy Subjects (clinicaltrials.gov) - Oct 13, 2022
P1, N=24, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Unknown status --> Completed Active, not recruiting --> Completed
- |||| HR17031 / Jiangsu Hengrui Pharma, long acting basal insulin (INS068) / Jiangsu Hengrui Pharma
Enrollment open: A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jul 27, 2022
P2, N=450, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| HR17031 / Jiangsu Hengrui Pharma, long acting basal insulin (INS068) / Jiangsu Hengrui Pharma
New P2 trial: A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - Apr 19, 2022
P2, N=450, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Enrollment closed: The Effect of SHR20004?Noiiglutide ? on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - Mar 15, 2022
P2, N=254, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- || noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Enrollment status: The Effect of SHR20004?Noiiglutide ? on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - Oct 12, 2021
P2, N=252, Enrolling by invitation, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Enrolling by invitation --> Active, not recruiting Recruiting --> Enrolling by invitation
- || HR17031 / Jiangsu Hengrui Pharma
Enrollment closed: Pharmacokinetics of HR17031 Injection in Healthy Subjects (clinicaltrials.gov) - Sep 23, 2021
P1, N=24, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Enrolling by invitation Not yet recruiting --> Active, not recruiting
- || HR17031 / Jiangsu Hengrui Pharma
New P1 trial: Pharmacokinetics of HR17031 Injection in Healthy Subjects (clinicaltrials.gov) - Sep 1, 2021
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Enrollment open: The Effect of SHR20004?Noiiglutide ? on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - Apr 27, 2021
P2, N=252, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P2 trial: The Effect of SHR20004?Noiiglutide ? on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - Mar 16, 2021
P2, N=252, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P2 trial: A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects. (clinicaltrials.gov) - Feb 21, 2019
P2, N=120, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P1 trial: Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients (clinicaltrials.gov) - Apr 25, 2016
P1, N=12, Recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- ||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers (clinicaltrials.gov) - Apr 21, 2016
P1, N=62, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- | noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers (clinicaltrials.gov) - Apr 21, 2016
P1, N=40, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.